Renal Cell Carcinoma News
A cumulative-use analysis suggests that NSAIDs, ACEis, and SSRIs improve disease-specific outcomes among patients with kidney cancer, and further that NSAIDs improve overall survival.
Thirty to 40% of patients with RCC relapse a median of 2 years after nephrectomy. The majority of relapses occur within 5 years.
A review of data from the CABOSUN and CheckMate-214 trials to determine the use of targeted therapy in metastatic renal cell carcinoma.
For CheckMate-025, 803 patients with RCC previously treated with anti-angiogenic therapy were assigned to receive IV nivolumab every 2 weeks or oral everolimus once daily.
Previous studies have associated miR-181a dysregulation with various cancers, such as acute lymphoblastic leukemia as well as colon, breast, and pancreatic cancers, but its role in ccRCC is unknown.
Patients in all subgroups who received adjuvant sunitinib had a DFS benefit compared with placebo, including patients who were at a higher risk of recurrence.
Researchers hypothesized that by reversing the order and administering targeted therapy prior to CN, tumor size would be reduced prior to surgery and lead to improved outcomes.
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
In the open-label, phase 2 CABOSUN trial, 157 patients with untreated, locally advanced or metastatic clear cell RCC were randomly assigned to receive cabozantinib or sunitinib.
The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).
Cabozantinib and nivolumab (CaboNivo) with or without ipilimumab (Ipi) demonstrated manageable safety profiles and durable clinical activity.
Researchers evaluated telomere length samples from 184 patients with von Hippel-Lindau syndrome to determine whether shortened telomere length can predict cancer risk.
Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.
Combining nivolumab with ipilimumab is safe, efficacious, and potentially improves overall survival among patients with metastatic renal cell carcinoma.
Savolitinib was tolerable, safe, and may have treatment potential for patients with MET-driven papillary renal cell carcinoma.
Downregulation of apoptosis stimulating of p53 protein 1 confers drug resistance and permits tumor growth in clear cell renal cell carcinoma.
Toxicity-driven dosing of sunitinib improved response rates and survival compared with historical standard dosing among patients with metastatic renal cell carcinoma.
Patients with a decline in HGF levels had longer overall survival than those with high levels at baseline and at 4 weeks.
A modified dosing schedule of sunitinib did not improve adverse events rates among patients with metastatic renal cell carcinoma.
Overall, 3.5 million cells were analyzed and 17 major tumor-associated macrophage phenotypes were identified.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Axillary Node Management for Breast Cancer: Is Less More?
- Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer
- Potentially Inappropriate Medications May Shorten Survival Among Elderly Patients With Lymphoma
- Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma
- The Potential of Radium-223 in Modern Prostate Cancer Treatment
- Colorectal Cancer Screening: Utility of Septin-9 Assays
- Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC
- Phase 2 Study of Nivolumab Plus Ipilimumab for Gastric, Ovarian, and Breast Cancer
- Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
- Priming Lung Cancer To Respond to Immunotherapy: Findings and Current Research